QRVO
31
2
AZO
50
2
V
66
8
FOX
42
2
LYB
39
2
AMGN
55
-8
PSX
44
2
SYK
55
15
M
52
4
SLB
41
2
PFG
52
2
MMC
54
6
WFC
71
13
EQT
59
2
DRI
54
-2
GT
58
2
SCHW
61
2
AIG
72
4
RRC
72
6
DO
73
7
QRVO
31
2
AZO
50
2
V
66
8
FOX
42
2
LYB
39
2
AMGN
55
-8
PSX
44
2
SYK
55
15
M
52
4
SLB
41
2
PFG
52
2
MMC
54
6
WFC
71
13
EQT
59
2
DRI
54
-2
GT
58
2
SCHW
61
2
AIG
72
4
RRC
72
6
DO
73
7
Financhill
Back

Inozyme Pharma Quote, Financials, Valuation and Earnings

He cracked the code to crypto

Now he says a new two-year bull market has begun. And he likes one altcoin above all others.
Buy
68

INZY
Inozyme Pharma

Last Price:
4.61
Seasonality Move:
-8.94%

7 Day Trial

ALL ACCESS PASS

$ 7

9,530x the last time this happened

Here's what our expert says you should buy before April 14.

Inozyme Pharma Price Quote

$4.61
-0.27 (-5.53%)
(Updated: May 7, 2024 at 6:55 PM ET)

Inozyme Pharma Key Stats

Buy
68
Inozyme Pharma (INZY) is a Buy
Day range:
$4.76 - $4.90
52-week range:
$2.69 - $7.80
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.15%
Volume:
354.5K
Avg. volume:
829.5K
1-year change:
-17.15%
Market cap:
$301.9M
Revenue:
$0
EPS:
$-1.39

How Much Does Inozyme Pharma Make?

Data Unavailable

Is Inozyme Pharma Growing As A Company?

Data Unavailable

Inozyme Pharma Stock Price Performance

  • Did Inozyme Pharma Stock Go Up Last Month?
    Inozyme Pharma share price went down by -23.87% last month
  • Did INZY's Share Price Rise Over The Last Year?
    INZY share price fell by -17.15% over the past 1 year

What Is Inozyme Pharma 52-Week High & Low?

Inozyme Pharma Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Inozyme Pharma?

  • How Much Debt Does Inozyme Pharma Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Inozyme Pharma Have?
    Cash and short term investments quarterly total is $188.6M
  • What Is Inozyme Pharma’s Book Value Per Share?
    Book value per share is 2.27

Is Inozyme Pharma Cash Flow Positive?

  • What Is INZY Cash Flow From Operations?
    Cash flow from operations (TTM) is -$70.7M
  • What Is Inozyme Pharma’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $126M
  • What Is Inozyme Pharma’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$53.6M

Inozyme Pharma Return On Invested Capital

Data Unavailable

Inozyme Pharma Earnings Date & Stock Price

Inozyme Pharma Competitors

  • Who Are Inozyme Pharma's Competitors?
    Below is a list of companies who compete with Inozyme Pharma or are related in some way:
    • Athira Pharma Inc (ATHA)
    • Disc Medicine Inc (IRON)
    • Kodiak Sciences Inc (KOD)
    • Phathom Pharmaceuticals Inc (PHAT)
    • Xeris Biopharma Holdings Inc (XERS)

Inozyme Pharma Dividend Yield

Data Unavailable

Inozyme Pharma Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -12.9%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 20.33
Upside from Last Price: 316.67%

Major Shareholders

  • How many INZY shares are owned by institutional investors?
    67.7M INZY shares are owned by institutional investors
  • How many INZY shares are owned by insiders?
    712.9K INZY shares are owned by insiders